Axogen Inc. logo

Axogen Inc. (LT3)

Market Closed
20 Feb, 07:01
XBER XBER
28. 40
0
0%
345.94M Market Cap
- P/E Ratio
4% Div Yield
0 Volume
-0.19 Eps
28.4
Previous Close
Day Range
28.4 28.4
Year Range
8.05 28.8
Want to track LT3 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LT3 earnings report is expected in 70 days (6 May 2026)

Summary

LT3 closed Friday higher at €28.4, an increase of 0% from Thursday's close, completing a monthly increase of 0% or €0. Over the past 12 months, LT3 stock gained 0%.
LT3 pays dividends to its shareholders, with the most recent payment made on Feb 12, 2010. The next estimated payment will be in 12 Feb 2011 on Feb 12, 2011 for a total of €1.
The last earnings report, released on Yesterday at 12:00 AM, missed the consensus estimates by -0.1%. On average, the company has fell short of earnings expectations by -0.06%, based on the last three reports. The next scheduled earnings report is due on May 06, 2026.
Axogen Inc. has completed 3 stock splits, with the recent split occurring on Jul 11, 1994.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

LT3 Chart

Similar

IZ6
AVI Ltd.
5.35
0%
Veradigm Inc.
7.7
0%
Spyre Therapeutics, Inc.
27.6
0%
3XV
XVIVO Perfusion AB
17.17
0%
LYF
EKF Diagnostics Holdings plc
0.26
0%
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript

Seekingalpha | 10 hours ago
AxoGen (AXGN) Q4 Earnings Miss Estimates

AxoGen (AXGN) Q4 Earnings Miss Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.

Zacks | 11 hours ago
Wasatch Micro Cap Fund Q4 2025 Performance Review

Wasatch Micro Cap Fund Q4 2025 Performance Review

Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and paninis, Mama's targets the deli area of grocery stores and warehouse clubs. On the downside, software distribution company Climb Global Solutions, Inc. was the Fund's leading laggard in the quarter.

Seekingalpha | 2 weeks ago

Axogen Inc. (LT3) FAQ

What is the stock price today?

The current price is €28.40.

On which exchange is it traded?

Axogen Inc. is listed on XBER.

What is its stock symbol?

The ticker symbol is LT3.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4%.

What is its market cap?

As of today, the market cap is 345.94M.

When is the next earnings date?

The next earnings report will release on May 06, 2026.

Has Axogen Inc. ever had a stock split?

Axogen Inc. had 3 splits and the recent split was on Jul 11, 1994.

Axogen Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Michael D. Dale CEO
XBER Exchange
US05463X1063 ISIN
US Country
451 Employees
12 Feb 2010 Last Dividend
11 Jul 1994 Last Split
27 Mar 1990 IPO Date

Overview

AxoGen, Inc., alongside its subsidiaries, plays a pivotal role in advancing the field of peripheral nerve regeneration and repair around the globe. This innovative company is focused on developing and bringing to market specialized technologies that address critical needs in nerve repair. By providing state-of-the-art solutions, AxoGen, Inc. is committed to improving the quality of life for patients suffering from peripheral nerve injuries. The company serves a diverse clientele, including hospitals, surgery centers, military hospitals, as well as plastic reconstructive, orthopedic, and hand surgeons, and oral and maxillofacial surgeons, operating out of its headquarters in Alachua, Florida.

Products and Services

  • Avance Nerve Graft

    A pioneering product in nerve repair, the Avance Nerve Graft is a biologically active, off-the-shelf processed human nerve allograft designed for bridging severed peripheral nerves. This innovative solution offers a significant advantage by eliminating the comorbidities associated with harvesting grafts from a second surgical site, thereby facilitating a more efficient and less invasive recovery for patients.

  • AxoGuard Nerve Connector

    This product takes advantage of a porcine submucosa extracellular matrix (ECM) to assist in the tensionless repair of severed peripheral nerves. The AxoGuard Nerve Connector facilitates the precise alignment and connection of nerve endings, promoting optimal healing and nerve function recovery.

  • AxoGuard Nerve Protector

    As a porcine submucosa ECM product, the AxoGuard Nerve Protector is utilized to wrap and safeguard damaged peripheral nerves. It plays a vital role in nerve reconstruction by reinforcing the repair process while preventing soft tissue attachments, thereby ensuring the integrity and functionality of the nerve post-repair.

  • Axoguard HA+ Nerve Protector

    This advanced version incorporates a processed porcine submucosa ECM base layer along with a hyaluronate-alginate gel coating. The Axoguard HA+ Nerve Protector is specifically designed to provide both short and long-term protection for peripheral nerve injuries, offering an enhanced barrier and healing environment.

  • Axoguard Nerve Cap

    The Axoguard Nerve Cap is crafted from a porcine submucosa ECM and is used to protect the end of a peripheral nerve. It effectively isolates the nerve from the surrounding tissues to minimize the development of symptomatic or painful neuroma, thereby contributing to a better patient outcome.

  • AxoTouch Two-Point Discriminator

    This specialized tool is employed for measuring the innervation density of the skin's surface area. The AxoTouch Two-Point Discriminator is an essential instrument for assessing the success of nerve repair and recovery, providing valuable feedback for surgeons and patients alike.

Contact Information

Address: 13631 Progress Boulevard
Phone: 386 462 6800